⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ESPR News
Esperion Therapeutics, Inc.
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
ESPR
The Connectivity Standards Alliance Announces Unify, Its Inaugural Event to Define the Future of Connectivity and Interoperability
prnewswire.com
SLAB
NXPI
AMZN
GOOG
AAPL
INTC
MSFT
NVDA
QCOM
AMBA
ON
TER
ADI
TXN
STM
CMCSA
FOR
LEG
NOC
RTO
SU
SM
TUYA
VZ
ESPR
ALGN
BRK.A
JNJ
V
PG
MA
KO
PEP
DIS
HD
CHTR
T
CSCO
IBM
CRM
ACN
ORCL
HPQ
DELL
MSI
MRVL
AMD
MU
WDC
STX
LRCX
KLAC
ASML
AMAT
MCHP
AVGO
ADSK
CDNS
SNPS
MPWR
RMBS
QRVO
SWKS
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
globenewswire.com
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
ESPR
Familial Hypercholesterolemia Market Intelligence Report 2025-2035 Featuring Regeneron, Amgen, Esperion, Aegerion, Novartis and Other Key Players - Precision Medicine Fuels Personalized Treatment Approaches
globenewswire.com
REGN
AMGN
ESPR
ARWR
Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
globenewswire.com
ESPR
Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
globenewswire.com
ESPR
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
globenewswire.com
ESPR
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
globenewswire.com
ESPR
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
ESPR